About The Neuramedy DealMy momma told me many times that I don't have anything good to say that I shouldn't say anything at all. I don't pay much attention to that and I don't much like the Neuramedy deal. It makes sense on some level, but the numbers are awful.
How can an xB3 license for Parkinson's disease (PD) be sold for an upfront payment that is so small that it's not material and reportable? How can any drug developed for such a huge indication like PD be worth only $70 million in milestones? (No mention of whether developmental or regulatory milestones are included. It looks like there are just commercial milestones and royalties, meaning way, way down the road.)
Even though the Neuramedy xB3 drug will have competing pipeline projects at both Neuramedy and Bioasis, it could still be a blockbuster drug that wouldn't exist without the key to the brain, xB3.
I have read several papers this morning that relate to PD, Neuramedy's approaches to PD and on related subjects. I just can't bring myself to write about it all today. I have a post underway but, look, there are reasons why the Bioasis share price jumped all the way back up to Monday's close, and has gone no further, so there's no hurry on this one.
I will say this. In the upcoming roadshow interviews, invitation only, I think you all should ask DrDR to explain why xB3 is turning out to be worth so little, because that looks like where this is going.
jd